Pediatric Brain Tumors Market

Key Highlights

• According to the study Johnson et al., there are >100 different histological subtypes of CNS tumors with the incidence of each varying by age and histologic subtype. Childhood CNS tumor incidence varies by country from 1.12–5.14 cases per 100,000 persons with the highest incidence in the United States.

• Pediatric Brain Tumors Market Companies working in the market are Laminar Pharmaceuticals, Cellectar Biosciences, Oncoceutics, Novartis, Ziopharm, Moleculin Biotech, Candel Therapeutics, Celgene, Kazia Therapeutics, and others.

• Pediatric Brain Tumors epidemiology is segmented as Total Pediatric Brain Tumors Incident Cases, Pediatric Brain Tumors Gender-specific Incident Cases, Pediatric Brain Tumors Diagnosed and Treatable Cases, and Pediatric Brain Tumors Type-specific Incident cases in the Pediatric Brain Tumors market report.

Request a sample to unlock the CAGR for  Pediatric Brain Tumor Market

DelveInsight's "Pediatric Brain Tumors Market Insights, Epidemiology, and Market Forecast — 2032" report delivers an in-depth understanding of the Pediatric Brain Tumors, historical and forecasted epidemiology as well as the Pediatric Brain Tumors market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2019 to 2032.

The Pediatric Brain Tumors market report provides current treatment practices, emerging drugs, Pediatric Brain Tumors market share of the individual therapies, current and forecasted Pediatric Brain Tumors Market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Pediatric Brain Tumors treatment practice/algorithm, and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019–2032

Pediatric Brain Tumors Disease Market: Understanding and Treatment Algorithm

The DelveInsight’s Pediatric Brain Tumors market report gives a thorough understanding of Pediatric Brain Tumors by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. Pediatric central nervous system (CNS) tumors are the second most common childhood malignancy and the most common solid tumor in children. Little is known regarding the pathogenesis of most brain tumors in children. There are genetic syndromes that can predispose patients to getting brain tumors, such as neurofibromatosis type 1 (NF-1), tuberous sclerosis, Li-Fraumeni syndrome, and other less common inherited conditions, such as Gorlin syndrome or Turcot syndrome. 

Symptoms of Pediatric Brain Tumors vary depending on size and location of tumor and can occur a bit differently in each child. Growing tumors may cause increased pressure on the brain in the limited space in the skull. This is called increased intracranial pressure or ICP. This is not usually the case in babies, since their skull bones have not fully grown together. The most common symptoms include, headache, nausea, and seizures.

Pediatric Brain Tumors Diagnosis

The first and foremost step in evaluating Pediatric Brain Tumors is obtaining a comprehensive medical history and physical examination of the child. Examination procedures for a brain tumor may include neurological exam, CT, PET or MRI scan, X-ray, angiogram, myelogram and lumbar puncture.

Pediatric Brain Tumors Treatment

Combination of surgery, radiation therapy, and chemotherapy are mainly used for the treatment of Pediatric Brain Tumors. Treatments that are fairly well-tolerated by the adult brain (such as radiation therapy) may prevent normal development of a child’s brain, especially in children younger than age five.

Pediatric Brain Tumors Epidemiology

The Pediatric Brain Tumors epidemiology section provides insights about historical and current Pediatric brain tumors patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

• According to the study Johnson et al., there are >100 different histological subtypes of CNS tumors with the incidence of each varying by age and histologic subtype. Childhood CNS tumor incidence varies by country from 1.12–5.14 cases per 100,000 persons with the highest incidence in the United States. 

• The disease epidemiology covered in the report provides historical as well as forecasted Pediatric Brain Tumors epidemiology [segmented as Total Incident Cases of Pediatric brain tumors, Gender-specific Incident Cases of Pediatric brain tumors, Diagnosed and Treatable Cases of Pediatric brain tumors, and Type-specific Incident cases of Pediatric brain tumors] in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the UK, and Japan from 2019 to 2032.

Country Wise- Pediatric Brain Tumors Epidemiology

This section provides a glimpse of the Pediatric Brain Tumors epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.

Learn more about the evolving epidemiology trends and key developments: Pediatric Brain Tumors Epidemiology Forecast
 

Pediatric Brain Tumors Recent Developments

• In January 2025, Koh Young Technology, a Korean medical robotics company, announced it received 510(k) clearance from the U.S. FDA for its Geniant Cranial brain surgery robot.

Pediatric Brain Tumors Drug Chapters

The drug chapter segment of the Pediatric Brain Tumors report encloses the detailed analysis of Pediatric Brain Tumors marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Pediatric Brain Tumors clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Pediatric Brain Tumors Marketed Drugs

AFINITOR (everolimus): Abbott

The US Food and Drug Administration (FDA) approved everolimus tablets for oral suspension (AFINITOR DISPERZ) as a new pediatric dosage form of everolimus (AFINITOR). It is used to treat patients with sub ependymal giant cell astrocytoma (SEGA), a rare brain tumor that cannot be treated with surgery. However, it is currently in development for other recurrent, progressive low-grade gliomas like pilocytic astrocytoma and pediatric progressive low-grade gliomas in children.

Note: Detailed Current therapies assessment will be provided in the full report of Pediatric Brain Tumors

Pediatric Brain Tumors Emerging Drugs

Everolimus (RAD001) is an orally administered drug, being developed by Novartis, that works by interrupting the PI3K/Akt/mTOR cell-signaling pathway that is overactive in certain tumors. The drug inhibits explicitly mTOR, a protein that may help many tumors grow, thereby stopping the hyperactivation. It binds to an intracellular protein, FKBP-12, resulting in an inhibitory complex formation with mTOR complex 1 (mTORC1) and thus inhibition of mTOR kinase activity. The drug has already been approved as an anti-cancer agent for other tumor types and is currently being investigated to treat low-grade gliomas.

Ad-RTS-hIL-12 + veledimex is a gene therapy, being developed by Ziopharm, for recurrent GBM (rGBM). Ad-RTS-hIL-12 is an adenoviral vector administered via a single injection into the tumor and engineered to express hIL-12, a powerful cytokine that has demonstrated the potential to stimulate a targeted, anti-tumor immune response. The expression of hIL-12 is controlled and modulated with the RheoSwitch Therapeutic System (RTS) by the small molecule veledimex, an activator ligand which has been shown to cross the blood brain barrier.

Laminar Pharmaceuticals’ LP561A1 is the first-in-class anticancer drug acting through cell membrane lipid modification. LP561A1 is an orally bioavailable synthetic derivative of oleic acid that crosses the Blood Brain Barrier and activates SMS1 expression with Ras signalling modulator effects, a key enzyme that regulates phospholipid, particularly sphingolipid, concentrations at the plasma membrane.

ONC201 is a highly selective antagonist of dopamine receptor D2 (DRD2) and ClpP agonist that is able to penetrate the blood-brain-barrier effectively. ONC201 engages proven anti-cancer pathways that lead to apoptosis in cancer cells.

CLR-131 being developed by Cellectar Biosciences is a small-molecule, cancer-targeting radiotherapeutic PDC designed to deliver cytotoxic radiation directly and selectively to cancer cells and cancer stem cells.

Moleculin Biotech is developing WP1066 (AflacST1901), an immune/transcription modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies. WP1066 is designed to target the STAT3 pathway in cancer cells, which makes these cells divide, increases new blood vessels to the tumor, causes the cancer cells to move throughout the body and brain, and avoids them being detected by the immune system. Targeting this pathway may cause the immune system to kill the cancer cells.

Note: Detailed emerging therapies assessment will be provided in the full report of Pediatric Brain Tumors

Pediatric Brain Tumors Market Outlook

Low-grade gliomas comprise several subgroups, including pilocytic, pilomyxoid, subependymal giant cell, and diffuse astrocytomas. Two cancer-predisposition syndromes, neurofibromatosis type 1 (NF1) and tuberous sclerosis complex, are associated with an increased frequency of pilocytic astrocytomas and subependymal giant cell astrocytomas, respectively. Extensive resection is the treatment goal for superficial lesions within the cerebral and cerebellar hemispheres. After complete resection, RT or chemotherapy is rarely warranted. Unfortunately, complete resection is not usually feasible for deep-seated, infiltrative tumors, such as those involving the hypothalamus and optic pathways, which have a worse prognosis than superficial lesions. The management of such tumors is made even more challenging by their often large size and frequent occurrence in young children, increasing the risks of adverse late effects from RT. Accordingly, conventional chemotherapy has been used during the last 2 decades to delay or avoid RT in young children.

Medulloblastomas are the most common malignant brain tumors in children. Overall, the outcome of children older than 3 years with medulloblastoma has improved significantly in the past 40 years with the use of craniospinal RT and multi-agent chemotherapy following an extensive resection. Unfortunately, surviving children experience a myriad of long-term debilitating sequelae associated with therapy. Although a subset of patients younger than 3 years at diagnosis, specifically those with nodular/desmoplastic tumors, have a good prognosis when treated with multi-agent chemotherapy combined with intrathecal methotrexate but no RT, the remaining patients, including those with the classic or large cell/anaplastic variants and/or metastatic disease, continue to experience poor outcomes despite the use of intensive therapies.

Malignant (high-grade) gliomas, such as anaplastic astrocytomas (WHO grade III) and glioblastomas (WHO grade IV), have a poor prognosis in children, as they do in adults. Unfortunately, progress in the management of these tumors has been frustratingly slow. Although the addition of nitrosourea-based chemotherapy to postoperative RT was shown more than 20 years ago to increase survival rates for patients with HGG compared to rates following treatment with RT alone, subsequent studies with different regimens have failed to further improve outcome. Two clinical factors most consistently associated with prognosis are extent of resection and tumor histology, with grade IV lesions having worse outcomes than grade III tumors and with lesions not amenable to extensive resection having a dismal prognosis. Levels of expression of methylguanine-DNA-methyltransferase, which confers resistance to alkylating chemotherapy, have also been adversely associated with outcome in some studies.

The dynamics of the Pediatric brain tumors is anticipated to change in the coming years owing to the improvement in the rise in number of healthcare spending across the world. Currently, there are several potential players with their promising therapies in the early and mid-stages of Pediatric brain tumors clinical trials development. There is an unmet clinical need for a therapeutic treatment that addresses the root cause of Pediatric brain tumors. Key players, such as Laminar Pharmaceuticals, Cellectar Biosciences, Oncoceutics, Novartis, Ziopharm, Moleculin Biotech, Candel Therapeutics, Celgene, Kazia Therapeutics, and others, are involved in developing drugs for the Pediatric brain tumors.

According to DelveInsight, Pediatric Brain Tumors market in 7MM is expected to witness a major change in the study period 2019-2032.

Analyst Commentary

• The pipeline of Pediatric Brain Tumors is very robust, many potential therapies are being investigated for the treatment of Pediatric Brain Tumors, and it is safe to predict that the treatment space will experience a significant impact on the market during the Pediatric brain tumors market forecast period.
• The expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and further improvement in the diagnosis rate, are likely to boost the growth of the Pediatric Brain Tumors market in the 7MM. Aside from that, the market size of Pediatric Brain Tumors may flourish due to increased research and development, label-expansion of approved therapies into other epilepsy in this field.
• The market growth of Pediatric Brain Tumors may offset by failures and/or discontinuation of the emerging therapies, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists.

Pediatric Brain Tumors Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Pediatric Brain Tumors market or expected to get launched in the market during the study period 2020-2034. The analysis covers Pediatric Brain Tumors market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. 

Note: Detailed emerging therapies assessment will be provided in the full report of Pediatric Brain Tumors.

Pediatric Brain Tumors Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Pediatric Brain Tumors key players involved in developing targeted therapeutics.

Pediatric Brain Tumors Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Pediatric Brain Tumors emerging therapies.

Learn more about the emerging therapies and key companies active in the therapeutics segment: Pediatric Brain Tumors Pipeline Insight

Reimbursement Scenario in Pediatric Brain Tumors

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current Pediatric brain tumors market trends, we take KOLs and SMEs ' opinions working in the Pediatric brain tumors domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Pediatric brain tumors market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Pediatric Brain Tumors Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Pediatric Brain Tumors Market Report Scope 

• The report covers the descriptive overview of Pediatric brain tumors, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
• Comprehensive insight has been provided into the Pediatric brain tumors epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Pediatric brain tumors are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Pediatric brain tumors market forecast and historical is included in the report, covering drug outreach in the 7MM
• Detailed Patient Based Market Forecasting determines the trends shaping and driving the global Pediatric brain tumors market

Pediatric Brain Tumors Market Report Highlights

• In the coming years, the Pediatric brain tumors market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Pediatric brain tumors R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major players are involved in developing therapies for Pediatric brain tumors. The launch of emerging therapies will significantly impact the Pediatric brain tumors market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Pediatric brain tumors
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging Pediatric brain tumors market trends, and comparative analysis of pipeline products with detailed Pediatric brain tumors clinical trial profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Pediatric Brain Tumors Report Insights

• Patient Based Market Forecasting
• Therapeutic Approaches
• Pediatric brain tumors Pipeline Analysis
• Pediatric brain tumors Market Size and Pediatric Brain Tumors Market Trends
• Market Opportunities
• Impact of upcoming Therapies

Pediatric Brain Tumors Report Key Strengths

• 11 Years Pediatric Brain Tumors Market Forecast
• 7MM Coverage
• Pediatric Brain Tumors Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Pediatric Brain Tumors Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness

Key Questions

Market Insights:

• What was the Pediatric brain tumors drug class share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Pediatric brain tumors total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings of the market across 7MM and which country will have the largest Pediatric brain tumors market size during the forecast period (2019-2032)?
• At what CAGR, the Pediatric brain tumors market is expected to grow by 7MM during the forecast period (2019-2032)?
• What would be the Pediatric brain tumors market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the Pediatric brain tumors market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Pediatric brain tumors?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan?
• What is the historical Pediatric brain tumors patient pool in seven major markets covering the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan?
• What would be the forecasted patient pool of Pediatric brain tumors in seven major markets covering the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population about Pediatric brain tumors?
• Out of all 7MM countries, which country would have the highest incident population of Pediatric brain tumors during the Pediatric brain tumors market forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow by 7MM during the Pediatric brain tumors market forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the Pediatric brain tumors treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Pediatric brain tumors in the US, Europe, and Japan?
• What are the Pediatric brain tumors marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many companies are developing therapies for the treatment of Pediatric brain tumors?
• How many therapies are in-development by each company for Pediatric brain tumors treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Pediatric brain tumors treatment?
• What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pediatric brain tumors therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pediatric brain tumors and its status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Pediatric brain tumors?
• What are the global historical and forecasted markets of Pediatric brain tumors?

Reasons to buy

• The Patient Based Market Forecasting analysis will help in developing business strategies by understanding trends shaping and driving the Pediatric brain tumors market
• Organize sales and marketing efforts by identifying the best opportunities for Pediatric brain tumors in the US, Europe (Germany, France, Italy, and Spain) and the UK .and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the Pediatric brain tumors market
• To understand the future market competition in the Pediatric brain tumors market